Results of a phase I/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (Bria-IMT) in metastatic breast cancer

Results of a phase I/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (Bria-IMT) in metastatic breast cancer

This Phase I/IIa open-label, single-arm clinical trial addressing advanced, refractory, metastatic breast cancer was conducted at six medical centers in the United States. We repeated inoculations with irradiated SV-BR-1-GM, a breast cancer cell line with antigen-presenting activity engineered to re...

Full description

Saved in:
Bibliographic Details
Main Authors: Charles L. Wiseman, Jarrod P. Holmes, Carmen Calfa, Shaker R. Dakhil, Saveri Bhattacharya, George E. Peoples, Markus D. Lacher, Miguel Lopez-Lago, Alex Kharazi, Giuseppe Del Priore, Mingjin Chang, Daniel L. Adams, William V. Williams
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
SV-BR-1-GM
breast cancer
immunotherapy
therapeutic cancer vaccine
histocompatibility markers
Trial registration
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2379864
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2024.2379864

Similar Items